Education
About Us
Working with TipRanks
Follow Us
Biofrontera AG (GB:0DOL)
LSE:0DOL
Earnings Data
Report Date
Jun 03, 2026TBA Not Confirmed
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 28, 2025
|% Change Since: 0.00%
|Next Earnings Date:Jun 03, 2026
Earnings Call Sentiment|Neutral
Biofrontera's Q1 2025 earnings call presented a positive outlook with revenue growth and key milestones in clinical trials and patent protection. However, challenges include cash flow issues and increased R&D and legal expenses.Company Guidance
During Biofrontera's first-quarter 2025 earnings call, the company reported a revenue increase of 9%, reaching $8.6 million, supported by a rise in Ameluz sales and the launch of the RhodoLED XL lamp. Operating expenses decreased to $13.1 million, with a notable 22.1% reduction in the cost of revenues. The company's net loss improved significantly to $4.2 million, or $0.47 per share, compared to $10.4 million, or $2.88 per share, in the prior year. Biofrontera also enhanced its gross profit and adjusted EBITDA, which rose from $4.4 million in the first quarter of 2024 to $4.6 million in 2025, driven by increased gross profit and strategic cost management. The company achieved several milestones, including patent protection for a new Ameluz formulation and progress in clinical trials aimed at expanding the product's indications. Biofrontera remains focused on sustaining revenue growth and achieving breakeven, leveraging an effective sales team and streamlined operations.Revenue Growth and Cost Management
Total revenues for Q1 2025 were $8.6 million, marking a 9% increase from the same period in 2024. Both cost of revenue and operating costs were lower than the previous year.
Patent Protection for Ameluz
A new formulation of Ameluz has been granted a patent valid until December 2043, providing 18.5 years of protection from generic competition.
Clinical Trial Progress
Enrollment of the final patient in Phase III trial for Ameluz for treating mild to moderate actinic keratoses. Another Phase III study milestone achieved for superficial basal cell carcinoma treatment.
Improved Financial Metrics
The net loss for Q1 2025 was reduced to $4.2 million from $10.4 million in Q1 2024. Adjusted EBITDA increased to $4.4 million.
GB:0DOL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0DOL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 28, 2025 | €14.30 | €14.30 | 0.00% |
Apr 24, 2025 | €14.30 | €14.30 | 0.00% |
Aug 28, 2024 | €14.30 | €14.30 | 0.00% |
May 31, 2024 | €14.30 | €14.30 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biofrontera AG (GB:0DOL) report earnings?
Biofrontera AG (GB:0DOL) is schdueled to report earning on Jun 03, 2026, TBA Not Confirmed.
What is Biofrontera AG (GB:0DOL) earnings time?
Biofrontera AG (GB:0DOL) earnings time is at Jun 03, 2026, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Biofrontera AG stock?
The P/E ratio of Biofrontera is N/A.
What is GB:0DOL EPS forecast?
Currently, no data Available